Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to -$100.6 million.

  • BeOne Medicines' Other Working Capital Changes fell 38541.29% to -$100.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$111.9 million, marking a year-over-year decrease of 107159.6%. This contributed to the annual value of -$45.1 million for FY2024, which is 8234.42% up from last year.
  • BeOne Medicines' Other Working Capital Changes amounted to -$100.6 million in Q3 2025, which was down 38541.29% from $75.1 million recorded in Q2 2025.
  • BeOne Medicines' Other Working Capital Changes' 5-year high stood at $150.2 million during Q1 2021, with a 5-year trough of -$381.4 million in Q4 2021.
  • In the last 5 years, BeOne Medicines' Other Working Capital Changes had a median value of -$32.9 million in 2022 and averaged -$42.5 million.
  • Within the past 5 years, the most significant YoY rise in BeOne Medicines' Other Working Capital Changes was 31647.96% (2021), while the steepest drop was 1400547.34% (2021).
  • Quarter analysis of 5 years shows BeOne Medicines' Other Working Capital Changes stood at -$381.4 million in 2021, then soared by 89.78% to -$39.0 million in 2022, then tumbled by 369.3% to -$183.0 million in 2023, then soared by 69.05% to -$56.6 million in 2024, then plummeted by 77.54% to -$100.6 million in 2025.
  • Its last three reported values are -$100.6 million in Q3 2025, $75.1 million for Q2 2025, and -$29.7 million during Q1 2025.